Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-06755992 |
Synonyms | |
Therapy Description |
PF-06755992 is a cancer vaccine consisting of a AdC68 adenovirus engineered to express prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA), which may result in the induction of cytotoxic T-lymphocyte (CTL) response against PSA, PSMA, PSCA-expressing tumor cells and tumor cell killing (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06755992 | PF 06755992|PF06755992 | PF-06755992 is a cancer vaccine consisting of a AdC68 adenovirus engineered to express prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA), which may result in the induction of cytotoxic T-lymphocyte (CTL) response against PSA, PSMA, PSCA-expressing tumor cells and tumor cell killing (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|